Neuropeptides stimulate human osteoblast activity and promote gap junctional intercellular communication

Neuropeptides

Volumn 47, Issue 3, 2013, Pages 179-186

  Ma, Wenhui ^a   Zhang, Xuemin ^b   Shi, Shushan ^c   Zhang, Yingze ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b Hebei Provincial National Defense Construction Hospital   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Gap junction intercellular communication; Neuropeptide; Osteoblast

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; NEUROPEPTIDE; NEUROPEPTIDE Y; OSTEOCALCIN; SUBSTANCE P; TYROSINE 3 MONOOXYGENASE; VASOACTIVE INTESTINAL POLYPEPTIDE;

ARTICLE; BONE REMODELING; CELL ACTIVITY; CELL COMMUNICATION; CELL FUNCTION; CELL STIMULATION; CELL VIABILITY; DOSE RESPONSE; ENZYME ACTIVITY; GAP JUNCTION; HUMAN; HUMAN CELL; IMMUNOREGULATION; NERVE ENDING; OSSIFICATION; OSTEOBLAST; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ALKALINE PHOSPHATASE; CELL COMMUNICATION; CELL SURVIVAL; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; GAP JUNCTIONS; HUMANS; NEUROPEPTIDES; OSTEOBLASTS; OSTEOCALCIN; STIMULATION, CHEMICAL;

EID: 84878421499     PISSN: 01434179     EISSN: 15322785     Source Type: Journal    
DOI: 10.1016/j.npep.2012.12.002     Document Type: Article

References (39)

1. Adamus M.A., Dabrowski Z.J. Effect of the neuropeptide substance P on the rat bone marrow-derived osteogenic cells in vitro. J. Cell. Biochem. 2001, 81:499-506.
2. Azuma H., Kido J., Ikedo D., Kataoka M., Nagata T. Substance P enhances the inhibition of osteoblastic cell differentiation induced by lipopolysaccharide from porphyromonas gingivalis. J. Periodontol. 2004, 75:974-981.
3. Bjurholm A., Kreicbergs A., Schultzberg M., Lerner U.H. Neuroendocrine regulation of cyclic AMP formation in osteoblastic cell lines (UMR-106-01, ROS 17/2.8, MC3T3-E1, and Saos-2) and primary bone cells. J. Bone Miner. Res. 1992, 7:1011-1019.
4. Cherian P.P., Siller-Jackson A.J., Gu S., Wang X., Bonewald L.F., Sprague E., Jiang J.X. Mechanical strain opens connexin43 hemichannels in osteocytes: a novel mechanism for the release of prostaglandin. Mol. Biol. Cell 2005, 16:3100-3106.
5. Chung D.J., Castro C.H., Watkins M., Stains J.P., Chung M.Y., Szejnfeld V.L., Willecke K., Theis M., Civitelli R. Low peak bone mass and attenuated anabolic response to parathyroid hormone in mice with an osteoblast-specific deletion of connexin43. J. Cell Sci. 2006, 119:4187-4198.
6. Civitelli R. Cell-cell communication in the osteoblast/osteocyte lineage. Arch. Biochem. Biophys. 2008, 473:188-192.
7. Civitelli R. Connexin43 modulation of osteoblast/osteocyte apoptosis: a potential therapeutic target?. J. Bone Miner. Res. 2008, 23:1709-1711.
8. Goto T., Nakao K., Gunjigake K.K., Kido M.A., Kobayashi S., Tanaka T. Substance P stimulates late-stage rat osteoblastic bone formation through neurokinin-1 receptors. Neuropeptides 2007, 41:25-31.
9. Hill E.L., Elde R. Distribution of CGRP-, VIP-, D beta H-, SP-, and NPY-immunoreactive nerves in the periosteum of the rat. Cell Tissue Res. 1991, 264:469-480.
10. Imai S., Matsusue Y. Neuronal regulation of bone metabolism and anabolism: calcitonin gene-related peptide-, substance P-, and tyrosine hydroxylase-containing nerves and the bone. Microsc. Res. Tech. 2002, 58:61-69.
11. Kawase T., Okuda K., Burns D.M. Immature human osteoblastic MG63 cells predominantly express a subtype 1-like CGRP receptor that inactivates extracellular signal response kinase by a cAMP-dependent mechanism. Eur. J. Pharmacol. 2003, 470:125-137.
12. Laird D.W. Closing the gap on autosomal dominant connexin-26 and connexin-43 mutants linked to human disease. J. Biol. Chem. 2008, 283:2997-3001.
13. Lecanda F., Warlow P.M., Sheikh S., Furlan F., Steinberg T.H., Civitelli R. Connexin43 deficiency causes delayed ossification, craniofacial abnormalities, and osteoblast dysfunction. J. Cell Biol. 2000, 151:931-944.
14. Lee N.J., Herzog H. NPY regulation of bone remodelling. Neuropeptides 2009, 43(6):457-463.
15. Lee N.J., Doyle K.L., Sainsbury A., Enriquez R.F., Hort Y.J., Riepler S.J., Baldock P.A., Herzog H. Critical role for Y1 receptors in mesenchymal progenitor cell differentiation and osteoblast activity. J. Bone Miner. Res. 2010, 25:1736-1747.
16. Lundberg P., Boström I., Mukohyama H., Bjurholm A., Smans K., Lerner U.H. Neuro-hormonal control of bone metabolism: vasoactive intestinal peptide stimulates alkaline phosphatase activity and mRNA expression in mouse calvarial osteoblasts as well as calcium accumulation mineralized bone nodules. Regul. Pept. 1999, 85:47-58.
17. Lundberg P., Lie A., Bjurholm A., Lehenkari P.P., Horton M.A., Lerner U.H., Ransjö M. Vasoactive intestinal peptide regulates osteoclast activity via specific binding sites on both osteoclasts and osteoblasts. Bone 2000, 27:803-810.
18. Lundberg P., Allison S.J., Lee N.J., Baldock P.A., Brouard N., Rost S., Enriquez R.F., Sainsbury A., Lamghari M., Simmons P., Eisman J.A., Gardiner E.M., Herzog H. Greater bone formation of Y2 knockout mice is associated with increased osteoprogenitor numbers and altered Y1 receptor expression. J. Biol. Chem. 2007, 282:19082-19091.
19. Ma W.H., Zhang X.M., Shi S.S., Li Y.F. Establishment and identification of a normal human osteoblast system. J. Clin. Rehabil. Tissue Eng. Res. 2010, 14:2661-2666.
20. Maayan C., Becker Y., Gesundheit B., Girgis S.I. Calcitonin gene related peptide in familial dysautonomia. Neuropeptides 2001, 35:189-195.
21. Maayan C., Bar-On E., Foldes A.J., Gesundheit B., Pollak R.D. Bone mineral density and metabolism in familial dysautonomia. Osteoporos. Int. 2002, 13:429-433.
22. Mach D.B., Rogers S.D., Sabino M.C., Luger N.M., Schwei M.J., Pomonis J.D., Keyser C.P., Clohisy D.R., Adams D.J., O'Leary P., Mantyh P.W. Origins of skeletal pain: sensory and sympathetic innervation of the mouse femur. Neuroscience 2002, 113:155-166.
23. McLachlan E., Plante I., Shao Q., Tong D., Kidder G.M., Bernier S.M., Laird D.W. ODDD-linked Cx43 mutants reduce endogenous Cx43 expression and function in osteoblasts and inhibit late stage differentiation. J. Bone Miner. Res. 2008, 23:928-938.
24. Offley S.C., Guo T.Z., Wei T., Clark J.D., Vogel H., Lindsey D.P., Jacobs C.R., Yao W., Lane N.E., Kingery W.S. Capsaicin-sensitive sensory neurons contribute to the maintenance of trabecular bone integrity. J. Bone Miner. Res. 2005, 20:257-267.
25. Opolka A., Straub R.H., Pasoldt A., Grifka J., Grässel S. Substance P and norepinephrine modulate murine chondrocyte proliferation and apoptosis. Arthritis Rheum. 2012, 64:729-739.
26. Pearson J., Dancis J., Axelrod F., Grover N. The sural nerve in familial dysautonomia. J. Neuropathol. Exp. Neurol. 1975, 34:413-424.
27. Persson E., Lerner U.H. The neuropeptide VIP regulates the expression of osteoclastogenic factors in osteoblasts. J. Cell. Biochem. 2011, 112:3732-3741.
28. Shi Y.C., Bladock P.A. Central and peripheral mechanisms of the NPY system in the regulation of bone and adipose tissue. Bone 2012, 50:430-436.
29. Shih C., Bernard G.W. Neurogenic substance P stimulates osteogenesis in vitro. Peptides 1997, 18:323-326.
30. Stains J.P., Civitelli R. Cell-to-cell interactions in bone. Biochem. Biophys. Res. Commun. 2005, 328:721-727.
31. Strange-Vognsen H.H., Arnbjerg J., Hannibal J. Immunocytochemical demonstration of pituitary adenylate cyclase activating polypeptide (PACAP) in the porcine epiphyseal cartilage canals. Neuropeptides 1997, 31(2):137-141.
32. Teixeira L., Sousa D.M., Nunes A.F., Sousa M.M., Herzog H., Lamghari M. NPY revealed as a critical modulator of osteoblast function in vitro: new insights into the role of Y1 and Y2 receptors. J. Cell. Biochem. 2009, 107:908-916.
33. Togari A., Arai M., Mizutani S., Mizutani S., Koshihara Y., Nagatsu T. Expression of mRNAs for neuropeptide receptors and beta-adrenergic receptors in human osteoblasts and human osteogenic sarcoma cells. Neurosci. Lett. 1997, 233:125-128.
34. Unger V.M., Kumar N.M., Gilula N.B., Yeager M. Three-dimensional structure of a recombinant gap junction membrane channel. Science 1999, 283:1176-1180.
35. Vignery A., McCarthy T.L. The neuropeptide calcitonin gene-related peptide stimulates insulin-like growth factor I production by primary fetal rat osteoblasts. Bone 1996, 18:331-335.
36. Villa I., Dal Fiume C., Maestroni A., Rubinacci A., Ravasi F., Guidobono F. Human osteoblast-like cell proliferation induced by calcitonin-related peptides involves PKC activity. Am. J. Physiol. Endocrinol. Metab. 2003, 284:E627-E633.
37. Wang L., Shi X., Zhao R., Halloran B.P., Clark D.J., Jacobs C.R., Kingery W.S. Calcitonin-gene-related peptide stimulates stromal cell osteogenic differentiation and inhibits RANKL induced NF-kappaB activation, osteoclastogenesis and bone resorption. Bone 2010, 46:1369-1379.
38. Watkins M., Grimston S.K., Norris J.Y., Guillotin B., Shaw A., Beniash E., Civitelli R. Osteoblast connexin43 modulates skeletal architecture by regulating both arms of bone remodeling. Mol. Biol. Cell 2011, 22:1240-1251.
39. Wróbel E., Leszczyńska J., Przybylski J. Role of gap junctions in bone tissue. Postepy Biochem. 2011, 57:411-417.